Methods of use of emulsion formulations of an nk-1 receptor antagonist
US-2024139106-A1 · May 2, 2024 · US
US10206906B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10206906-B2 |
| Application number | US-201615159980-A |
| Country | US |
| Kind code | B2 |
| Filing date | May 20, 2016 |
| Priority date | May 22, 2015 |
| Publication date | Feb 19, 2019 |
| Grant date | Feb 19, 2019 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
It is provided an anti-microbial composition comprising a phenolic-rich extract such as a phenolic-rich maple syrup extract (PRMSE) and at least one antibiotic and a method of treating a bacterial infection comprising administering to a subject in need thereof a phenolic-rich extract and at least one antibiotic.
Opening claim text (preview).
What is claimed is: 1. An anti-microbial composition with synergistic effect comprising a phenolic-rich maple syrup extract and at least one antibiotic. 2. The composition of claim 1 , wherein the at least one antibiotic is a fluoroquinolone antibiotic, a β-lactam antibiotic, aminoglycoside, polyketides, glycopeptides, benzenoids, macrolides, ansamycins, sulfonamides, chloramphenicol, oxazolidinones, carboxylic acids antibiotic, organic phosphonic acids antibiotic, quinolones and their derivatives. 3. The composition of claim 1 , wherein the at least one antibiotic is at least one of ciprofloxacin, carbenicillin, ampicillin, penicillin, kanamycin, gentamycin, tetracycline, levofloxacin, trimethoprim, sulfamethoxazole, norfloxacin, nitrofurantoin, fosfomycin, azithromycin, minocycline, am ikacin, cephalosporin, erythromycin, daptomycin, vancomycin and their derivatives. 4. The composition of claim 1 , wherein the phenolic-rich maple syrup extract is from Acer nigrum, Acer lanum, Acer acuminatum, Acer albopurpurascens, Acer argutum, Acer barbinerve, Acer buergerianum, Acer caesium, Acer campbellii, Acer campestre, Acer capillipes, Acer cappadocicum, Acer carpinifolium, Acer caudatifolium, Acer caudatum, Acer cinnamomifolium, Acer circinaturn, Acer cissifolium, Acer crassum, Acer crataegifolium, Acer davidii, Acer decandrum, Acer diabolicum, Acer distylum, Acer divergens, Acer erianthum, Acer erythranthum, Acer fabri, Acer garrettii, Acer glabrum, Acer grandidentatum, Acer griseum, Acer heldreichii, Acer henryi, Acer hyrcanum, Acer ibericum, Acer japonicum, Acer kungshanense, Acer kweilinense, Acer laevigatum, Acer laurinum, Acer lobelii, Acer lucidum, Acer macrophyllum, Acer mandshuricum, Acer maximowiczianum, Acer miaoshanicum, Acer micranthum, Acer miyabei, Acer mono, Acer mono×, Acer truncatum, Acer monspessulanum, Acer negundo, Acer ningpoense, Acer nipponicum, Acer oblongum, Acer obtusifolium, Acer oliverianum, Acer opalus, Acer palmatum, Acer paxii, Acer pectinatum, Acer pensylvanicum, Acer pentaphyllum, Acer pentapomicum, Acer pictum, Acer pilosum, Acer platanoides, Acer poliophyllum, Acer pseudoplatanus, Acer pseudosieboldianum, Acer pubinerve, Acer pycnanthum, Acer rubrum, Acer rufinerve, Acer saccharinum, Acer saccharum, Acer sempervirens, Acer shirasawanum, Acer sieboldianum, Acer sinopurpurescens, Acer spicatum, Acer stachyophyllum, Acer sterculiaceum, Acer takesimense, Acer tataricum, Acer tegmentosum, Acer tenuifolium, Acer tetramerum, Acer trautvetteri, Acer triflorum, Acer truncatum, Acer tschonoskii, Acer turcomanicum, Acer ukurunduense, Acer velutinum, Acer wardii, Acer×peronai , or Acer×pseudoheldreichii. 5. The composition of claim 1 , wherein said composition reduces biofilm formation of a bacterial strain. 6. The composition of claim 1 , wherein the anti-microbial composition is against Gram-negative or Gram-positive bacteria. 7. The composition of claim 1 , wherein the anti-microbial composition is against a bacterial strain of Escherichia coli, Proteus mirabilis, Pseudomonas aeruginosa, Salmonella species, Enterobacter cloacae, Burkholderia cepacia, Chromobacterium violaceum, Klebsiella pneumoniae, Helicobacter pylori, Acinetobacter baumannii, Vibrio cholera, Mycoplasma pneumoniae, Neisseria gonorrhoeae, Legionella pneumophila, Serratia species, Shigella species, Rickettsia rickettsia, Chlamydia pneumoniae, Mycobacterium tuberculosis, Yersinia species, Moraxella catarrhalis or Proteobacteria pathogens. 8. The composition of claim 1 , wherein the extract comprises a catechol, a catechaldehyde, a gallic acid, a syringaldehyde, a vanillin, and/or a hydroxybenzoic acid. 9. The composition of claim 1 , wherein said composition represses the expression of a gene associated with multiple drug resistance, motility, virulence determinants, adhesion and/or biofilm formation. 10. The composition of claim 9 , wherein said gene associated with multiple drug resistance is emrA, acre, marC, acrA, oprM, mexA or mexX. 11. The composition of claim 9 , wherein said gene associated with motility is fliC, flhD, motB, fimH, fimA, papA2, flaA, fleQ. 12. The composition of claim 9 , wherein said gene associated with virulence determinants is chuA, cysJ, plcH, phzS or pvdA. 13. The composition of claim 9 , wherein said gene associated with adhesion is fimH, fimA, papA2, atfB, cupA1 or pelA. 14. The composition of claim 9 , wherein said gene associated with biofilm formation is uvrY, ureD or lasB. 15. A method of treating a bacterial infection comprising administering to a subject in need thereof the anti-microbial composition of claim 1 .
Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00 · CPC title
Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin · CPC title
Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula [IMAGE cpc-sch-A61K-0952.gif], e.g. penicillins, penems · CPC title
Aceraceae (Maple family) · CPC title
Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.